Dostarlimab: tested in a combination
38 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial CancerRecruitingNCT07867002Phase 3Report a problem
- Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingNCT07860450Phase 3Report a problem
- Impact of Circadian Rhythm on ImmunotherapyRecruitingNCT07224971Phase 2Report a problem
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)RecruitingNCT07108270Phase 2Report a problem
- DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic CancerRecruitingNCT06757244Phase 2Report a problem
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingNCT05700721Phase 2Report a problem
- Cabozantinib and Dostarlimab in Recurrent Gynecologic CarcinosarcomaRecruitingNCT05559879Phase 1/2Report a problem
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingNCT05526989Phase 2Report a problem
- Niraparib and Dostarlimab in HRD Solid TumorsRecruitingNCT04983745Phase 2Report a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingNCT04817956Phase 2Report a problem
- Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCCRecruitingNCT04681469Phase 2Report a problem
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsRecruitingNCT04165772Phase 2Report a problem
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingNCT03651206Phase 2/3Report a problem
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMTerminatedNCT06655818Phase 1/2Results postedReport a problem
- Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyActive, not recruitingNCT04655976Phase 2/3Results postedReport a problem
- Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)TerminatedNCT04544995Phase 1Results postedReport a problem
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results postedReport a problem
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerActive, not recruitingNCT03602859Phase 3Results postedReport a problem
- Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsCompletedNCT03308942Phase 2Results postedReport a problem
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedNCT03307785Phase 1Results postedReport a problem
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Active, not recruitingNCT06472076Phase 3Report a problem
- Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDerWithdrawnNCT06385548Phase 1/2Report a problem
- Niraparib and Dostarlimab for Patients with MMR-D/MSI-H Colorectal CancersWithdrawnNCT06365970Phase 2Report a problem
- A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerActive, not recruitingNCT06317311Phase 2Report a problem
- A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)Active, not recruitingNCT06023862Phase 2Report a problem
- Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous CarcinomaActive, not recruitingNCT05870761Phase 2Report a problem
- Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05784012Phase 1/2Report a problem
- Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi SarcomaActive, not recruitingNCT05646082Phase 1Report a problem
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First LineActive, not recruitingNCT05201547Phase 3Report a problem
- Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPiWithdrawnNCT05126342Phase 2Report a problem
- UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLCStatus unknownNCT04940637Phase 2Report a problem
- Maintenance Niraparib and Dostarlimab in Advanced CholangiocarcinomaWithdrawnNCT04895046Phase 2Report a problem
- Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerActive, not recruitingNCT04837209Phase 2Report a problem
- Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and DostarlimabTerminatedNCT04779151Phase 2Report a problem
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04673448Phase 1Report a problem
- A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerActive, not recruitingNCT03981796Phase 3Report a problem
- Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian CancerWithdrawnNCT03806049Phase 3Report a problem
- TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver CancerActive, not recruitingNCT03680508Phase 2Report a problem